trimetrexate has been researched along with Lymphoma, Large B-Cell, Diffuse in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Lymphoma, Large B-Cell, Diffuse: Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robson, C | 1 |
| Meek, MA | 1 |
| Grunwaldt, JD | 1 |
| Lambert, PA | 1 |
| Queener, SF | 1 |
| Schmidt, D | 1 |
| Griffin, RJ | 1 |
1 other study available for trimetrexate and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Survival; Folic Acid Antagonists; Indicators and Reagents; Kine | 1997 |